HRTS Tema GLP-1, Obesity & Cardiometabolic ETF
- 34.440
- -0.160-0.46%
DexCom Price Target Cut to $75.00/Share From $120.00 by Morgan Stanley
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Robust CMI Drug Sales and Synergistic Commercial Strategies Bolster Buy Rating for Cytokinetics
BTIG Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $120
Oppenheimer Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $115
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $145
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Tenaya Therapeutics (TNYA) and Cue Biopharma (CUE)
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From RBC Capital
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)
Raymond James Adjusts Price Target on DexCom to $115 From $160
Dexcom: A Cautious Hold Amid Competitive Challenges and Operational Headwinds
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
Vertex Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500